Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Johanna M.T. Beerthuijzen"'
Publikováno v:
Journal of leukocyte biology, vol 104, iss 3
Immunotherapy has achieved breakthrough status in many advanced stage malignancies and is rapidly becoming the fourth arm of cancer treatment. Although cancer immunotherapy has generated significant excitement because of the potential for complete an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d4631a9a9ed2710b396d6f49e1b3802
https://escholarship.org/uc/item/96w7w1dr
https://escholarship.org/uc/item/96w7w1dr
Autor:
Deborah Collyar, Lyndsay Harris, Janice M. Mehnert, Larry Rubinstein, Arta M. Monjazeb, Johanna M.T. Beerthuijzen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 23, iss 17
The development of immunotherapy is an important breakthrough for the treatment of cancer, with antitumor efficacy observed in a wide variety of tumors. To optimize immunotherapy use, approaches must be developed to identify which patients are likely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::badd01d472cb73881a6a712a545735c8
https://escholarship.org/uc/item/7618k4br
https://escholarship.org/uc/item/7618k4br
Autor:
Christine Mall Minnar, Gail D. Sckisel, Johanna M.T. Beerthuijzen, Ethan G. Aguilar, Annie Mirsoian, Marka Crittenden, Bruce R. Blazar, Arta M. Monjazeb, William J. Murphy
Publikováno v:
The Journal of Immunology. 198:120.2-120.2
Cancer immunotherapies (IT) are quickly becoming frontline therapies for a variety of cancers and are often immunostimulatory in nature. We have previously demonstrated that systemic administration of strong immunostimulatory regimens in mice resulte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::281605ac6a138b6ea2e398140c5d86e0
https://doi.org/10.4049/jimmunol.198.supp.120.2
https://doi.org/10.4049/jimmunol.198.supp.120.2
Autor:
Erica Siera-de Koning, Manon M. H. Huibers, Johanna M.T. Beerthuijzen, Roel A. de Weger, Rianne Kruit, Nicolaas de Jonge, Ton Peeters, Alison J. Gareau, Timothy D.G. Lee, Hannah Feringa, Aryan Vink
Publikováno v:
Journal of Heart and Lung Transplantation, 34(5), 734. Elsevier USA
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a multifactorial pathology limiting the survival of cardiac transplants. The etiology of CAV is unclear, but antibody-mediated and cellular-mediated responses have been implicated. We, and others, h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e48d81eff36ced8a5720c23422a2a3
https://pubmed.ncbi.nlm.nih.gov/25655346
https://pubmed.ncbi.nlm.nih.gov/25655346